Physician profile
Gil E Johnson
NPI 1356563241
$984.14
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $177 · 2021: $104 · 2022: $86.28 · 2023: $98.34 · 2024: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $285.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $247.93 | 2019-2020 | |
| Lilly USA, LLC | $152.53 | 2019-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $101.63 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.27 | 2019-2024 | |
| Glaxosmithkline, LLC. | $86.47 | 2021 | |
| Phadia US INC. | $85.87 | 2024 | Immunocap |
| Otsuka America Pharmaceutical, INC. | $65.38 | 2023 | Rexulti |
| Amarin Pharma, INC. | $46.89 | 2022 | |
| Phathom Pharmaceuticals, INC. | $27.72 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $26.56 | 2024 | Airsupra |
| Abbott Laboratories | $21.84 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.89 | 2023 | Seglentis |
| Currax Pharmaceuticals LLC | $14.16 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gil Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.